1. 1. Bade BC and Dela Cruz CS (2020) Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med, 41(1): 1-24. [DOI:10.1016/j.ccm.2019.10.001]

2. Nasim F, Sabath BF, Eapen GA (2019) Lung Cancer. Med Clin North Am, 103(3): 463-473. [DOI:10.1016/j.mcna.2018.12.006]

3. de Sousa VML and Carvalho L (2018) Heterogeneity in Lung Cancer. Pathobiology, 85(1-2): 96-107. [DOI:10.1159/000487440]

4. Jones GS and Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond), 18(2): s41-s46. [DOI:10.7861/clinmedicine.18-2-s41]

5. Berzenji L and Van Schil PE (2019) Surgery or stereotactic body radiotherapy for early-stage lung cancer: two sides of the same coin? Eur Respir J, 53(6). [DOI:10.1183/13993003.00711-2019]

6. Vodicka J, Pesta M, Kulda V, et al. (2020) Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure. Cells, 9(12). [DOI:10.3390/cells9122611]

7. Nooreldeen R and Bach H (2021) Current and future development in lung cancer diagnosis. Int J Mol Sci, 22(16). [DOI:10.3390/ijms22168661]

8. Faria SC, Sagebiel T, Patnana M, et al.(2019) Tumor markers: myths and facts unfolded. Abdom Radiol (NY), 44(4): 1575-1600. [DOI:10.1007/s00261-018-1845-0]

9. Dong X, Men X, Zhang W, Lei P (2014) Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer, 51(3): e72-6. [DOI:10.4103/0019-509X.154049]

10. Dal Bello MG, Filiberti RA Alama A, et al. (2019) The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med, 17(1): 74. [DOI:10.1186/s12967-019-1828-0]

11. Wojcik E and Kulpa JK (2017) Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response. Lung Cancer (Auckl), 8: 231-240. [DOI:10.2147/LCTT.S149516]

12. Jiang ZF, Wang M, Xu JL, (2018) Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci, 194: 1-6. [DOI:10.1016/j.lfs.2017.12.020]

13. Wu F, Wang L, Zhou C, (2019) Lung cancer in China: current and prospect. Curr Opin Oncol, 33(1): 40-46. [DOI:10.1097/CCO.0000000000000703]

14. Fu L, Wang R, Yin L, et al. (2019) CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis. Int J Biol Markers, 34(3): 251-261. [DOI:10.1177/1724600819868234]

15. Grunnet M and Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2): 138-43. [DOI:10.1016/j.lungcan.2011.11.012]

16. Dong A, Zhang J, Chen X, et al. (2019) Diagnostic value of ProGRP for small cell lung cancer in different stages. J Thorac Dis, 11(4): 1182-1189. [DOI:10.21037/jtd.2019.04.29]

17. Zhou W, YangY, Wang Z, (2021) Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on lung cancer patients. J Healthc Eng, 2021: 6929971. [DOI:10.1155/2021/6929971]

18. Zhang L, Liu D, Li L, et al. (2017) The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer, 17(1): 96. [DOI:10.1186/s12885-017-3070-6]

19. Zhang HQ, Wang RB, Yan HJ, et al. (2012) Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev, 13(1): 199-203. [DOI:10.7314/APJCP.2012.13.1.199]

20. Kuang LI, Song WJ, Qing HM, et al. (2015) CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis. Genet Mol Res, 14(2): 3921-31. [DOI:10.4238/2015.April.27.6]

21. Hanada S, Nishiyama N, Mizuguchi S, et al. (2013) Clinicopathological significance of combined analysis of cytokeratin19 expression and preoperative serum CYFRA21-1 levels in human lung squamous cell carcinoma. Osaka City Med J, 59(1): 35-44.

22. Lu L, Zha Z, Zhang P, et al. (2021) NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process. Int J Med Sci, 18(16): 3768-3779. [DOI:10.7150/ijms.58415]

23. Lyubimova NV, Kuz'minov AE, Markovich AA, et al. (2022) Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer. Bull Exp Biol Med, 173(2): 257-260. [DOI:10.1007/s10517-022-05529-9]

24. Molina R, Filella X, Augé JM (2004) ProGRP: a new biomarker for small cell lung cancer. Clin Biochem, 37(7): 505-11. [DOI:10.1016/j.clinbiochem.2004.05.007]

25. Wójcik E, Kulpa JK, Sas-Korczyńska B, et al. (2008) ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res, 28(5b): 3027-33.

26. Lakemeyer L, Sander S, Wittau M, et al. (2021) Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. Diseases, 9(1): 21. [DOI:10.3390/diseases9010021]

27. Hall C, Clarke L, Pal A, et al. (2019) A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol, 35(6): 294-305. [DOI:10.3393/ac.2019.11.13]

28. Lee TH, Kim JS, Baek SJ, et al. (2023) Diagnostic accuracy of carcinoembryonic antigen (CEA) in detecting colorectal cancer recurrence depending on its preoperative level. J Gastrointest Surg, 27(8): 1694-1701. [DOI:10.1007/s11605-023-05761-2]

29. Hao C, Zhang G, Zhang L (2019) Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci, 162: 213-227. [DOI:10.1016/bs.pmbts.2018.12.011]

30. Cheng C, Yang Y, Yang W, et al. (2022) The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis. Expert Rev Respir Med, 16(1): 99-108. [DOI:10.1080/17476348.2021.1941885]

31. Hiraoka K and Horie A (1988) Immunohistochemical study of carcinoembryonic antigen (CEA) in lung carcinoma by five monoclonal antibodies. J uoeh, 10(3): 237-46. [DOI:10.7888/juoeh.10.237]

32. Wang L, Wang D, Zheng G, et al. (2016) Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers, 31(1): e80-7. [DOI:10.5301/jbm.5000177]